The BK virus infection market is expanding due to increased awareness and advancements in diagnostic technologies. Rising kidney transplant procedures and the subsequent need for effective treatments and management of BK virus in immunocompromised patients are driving market growth. LAS VEGAS , July 4, 2024 /PRNewswire/ -- DelveInsight's BK Virus Infection Market Insights report includes a comprehensive understanding of current treatment practices, BK virus infection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ].
Key Takeaways from the BK Virus Infection Market Report According to DelveInsight's analysis, the market size for BK virus infection is expected to grow significantly by 2034. BKV infections generally occur in patients, who undergo transplantation or surgical procedures. Viral infections after renal transplantation have emerged as an important cause of allograft loss.
It affects about 15% of renal transplant recipients in the first post-transplant year and lacks an effective prophylaxis strategy. Leading BK virus infection companies such as Memo Therapeutics, Vera Therapeutics, SymBio Pharmaceuticals , and others are developing novel BK virus infection drugs that can be available in the BK virus infection market in the coming years. The promising BK virus infection therapies in.